Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M, Torrent C, Reinares M, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.

Kessing LV, Andersen PK. Evidence for clinical progression of unipolar and bipolar disorders. Acta Psychiatr Scand.2017;135:51-64.

Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand. 2016;134:91-103.

Suh JS, Schneider MA, Minuzzi L, MacQueen GM, Strother SC, Kennedy SH, et al. Cortical thickness in major depressive disorder: a systematic review and meta-analysis. Prog
Neuropsychopharmacol Biol Psychiatry. 2019;88:287-302.

Syan SK, Smith M, Frey BN, Remtulla R, Kapczinski F, Hall GBC, et al. Resting-state functional connectivity in individuals with bipolar disorder during clinical remission: a systematic review. J Psychiatry Neurosci. 2018;43:298-316.

Mansur RB, Santos CM, Rizzo LB, Asevedo E, Cunha GR, Noto MN, et al. Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. Bipolar Disord. 2016;18:373-8.

Mansur RB, Rizzo LB, Santos CM, Asevedo E, Cunha GR, Noto MN, et al. Impaired glucose metabolism moderates the course of illness in bipolar disorder. J Affect Disord. 2016;195:57-62.

SayuriYamagata A, Brietzke E, Rosenblat JD, Kakar R, McIntyre RS. Medical comorbidity in bipolar disorder: the link with metabolic-inflammatory systems. J Affect Disord. 2017;211:99-106.

McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24:69-81.

Brietzke E, Stabellini R, Grassi-Oliveira R, Lafer B. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectr. 2011;16:157-68.